In the name of Working group of the bioregions of Germany (AK-BioRegions) wants that BioRN Life Science Cluster Rhine-Neckar this year virtual presentation of the EY Biotech Report on Tuesday, July 13.07.2021, 15 at XNUMX p.m
During the pandemic, the innovative strength of German biotech companies in particular became impressively visible. It showed that this industry can show the way out of the crisis through tests, diagnostics, therapies and vaccines. Biotechnology has thus become the focus of attention - in society, in politics, the media and among investors. In many areas, the sector was able to develop new dynamics and achieve records in financing, in turnover, in the number of employees and in expenditure on research and development. Biotechnology is thus at a turning point, at a "tipping point", as described in EY's German Biotechnology Report 2021. The central question: In which direction will the sector develop after the pandemic? The report provides the answers. It shows which opportunities are now arising, which new challenges are arising and what needs to be done in order to use the momentum in the long term.
Programme, moderated by Julia Schaft, Managing Director, BioRN:
- Welcome on behalf of the AK BioRegio - André Hofmann (CEO, biosaxony e. V.)
- Presentation of the EY report – Alexander W. Nuyken (Head of Life Sciences Strategy and Transactions EMEIA)
- SprinD Challenge: Leaping Innovations to Combat Viral Infections – Jano Costard (Challenge Officer, SprinD)
- Farewell (prev. 16:30 p.m.)
We ask that you find out about this Link to register for free. You will receive the access data shortly before the event.